Considerations for diverse RYR1 variants in malignant hyperthermia susceptible patients: a report of two cases Authors: Yan Fang, Wei Mei, Jiangjiang Bi Published: 2026 ABSTRACT AbstractMalignant hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder primarily triggered by halogenated volatile anesthetics, succinylcholine, or cisatracurium. This report describes two cases exhibiting typical MH symptoms, including hyperthermia, hypercarbia, tachycardia, and acidosis, but with notable differences in the time of onset and symptom severity. The variable expression of MH may be influenced by multiple factors, such as the potency of the triggering agent, its dosage, the duration of exposure, and the “incomplete penetrance” of genetic variants. The novel RYR1 gene variants reported in this study may contribute to the Genomic Variant Database for this condition.Keywords: General anesthesia, Gene variants, Incomplete penetrance, Malignant hyperthermia, Scoliosis Over the past decade, two patients undergoing orthopedic surgeries in our hospital have met the MH Clinical Grading Scale (CGS) criteria [1]. Given that variants in the RYR1 (ryanodine receptor 1) protein are the most common cause of MH susceptibility, accounting for up to 76% of all cases [2], genetic testing involving sequencing of the entire RYR1 gene was performed, revealing three missense variants in these two patients. Compared to the first case, the second patient was nearly misdiagnosed due to a prior history of uneventful general anesthesia for lumbar internal fixation. Both cases deviated from previously reported typical presentations, leading to a lack of immediate definitive diagnosis. Understanding why atypical MH is not always easily identified warrants careful consideration. In the following sections, we detail these two MH cases, compare their clinical features and outcomes, and explore the association between RYR1 variants and MH phenotypes. We aim to challenge the stereotypical perception of MH as a uniformly “sudden” event, thereby facilitating the early and rapid administration of dantrolene. Case presentations Case 1 The first patient, a 23-year-old female with no prior surgical or family history of anesthetic complications, underwent corrective scoliosis surgery under general anesthesia. Anesthesia was induced with propofol, sufentanil and rocuronium, and maintained with dexmedetomidine, remifentanil and sevoflurane. During the procedure, a severe MH crisis developed. Approximately 215 min after surgery commenced, her heart rate gradually increased to 90 beats·min⁻¹, and insufficient muscle relaxation was noted by the surgeon despite adequate neuromuscular blockade. Arterial blood gas analysis revealed acidosis with a pH of 7.23, PaCO₂ of 64.2 mmHg, K⁺ of 4.3 mmol/L, and a base excess of − 0.4 mEq/L. Subsequently, her core body temperature rapidly rose to 41.2 °C, and her heart rate increased to 135 beats·min⁻¹. A subsequent blood gas analysis showed a PaCO₂ of 107 mmHg, prompting immediate suspicion of MH. Sevoflurane was promptly discontinued. The patient’s blood pressure dropped to 48/38 mmHg and remained unresponsive to high doses of norepinephrine. However, dramatic clinical improvement followed rapid administration of dantrolene. The patient was transferred to the intensive care unit (ICU) for 8 days, receiving two additional doses of dantrolene. Major complications of MH ensued, including disseminated intravascular coagulation (DIC), renal failure, myocardial injury, reduced cardiac function, and pulmonary edema. Management included high-volume plasma exchange and continuous renal replacement therapy (CRRT). The patient made a full recovery 8 days after ICU admission. With informed consent, direct sequencing of the RYR1 gene was performed, identifying two novel heterozygous variants. The first was a C-to-T base exchange (c.4718 C > T) in exon 33, inherited maternally. The second was an A-to-G substitution (c.9100 A > G) in exon 60, inherited paternally. Case 2 The second patient was a 31-year-old male who had previously undergone lumbar internal fixation under general anesthesia without incident one year prior and was now presenting for removal of the internal fixation. General anesthesia was induced with etomidate, sufentanil and cisatracurium, and maintained with remifentanil, propofol, and sevoflurane. After 430 min, sudden tachycardia occurred, with the heart rate rising to 140 bpm and body temperature rapidly increasing from 37.5 °C to 41.2 °C. Blood transfusion was immediately halted. Administration of 0.5 g methylprednisolone and 50 mg diclofenac sodium provided no relief. Blood gas analysis indicated hypercapnia (PaCO₂: 95.4 mmHg) and hyperkalemia (K⁺: 5.1 mmol·L⁻¹), suggesting MH as a cause of the internal environment disturbance. Although no muscle rigidity was observed and the patient had a history of uneventful sevoflurane anesthesia, sevoflurane was discontinued and replaced with a propofol infusion. Twenty minutes later, blood-gas analysis revealed an extremely high PaCO₂ (103 mmHg). The heart rate increased to 150 bpm, and body temperature reached 41.2 °C. Diagnosing MH remained challenging due to atypical manifestations. Notably, hyperthermia and hypercapnia were partially alleviated by physical cooling and hyperventilation prior to dantrolene treatment, and blood pressure remained relatively stable throughout. Dantrolene administration further improved symptoms. Consequently, a definitive MH diagnosis could not be established immediately. The patient’s anesthesia recovery was not significantly delayed; he was successfully extubated and admitted to the ICU. Three hours later, elevated cardiac troponin I (215.9 pg/mL) indicated myocardial injury. Sharply increased plasma myoglobin and creatine kinase levels provided evidence of skeletal muscle injury, while only mild coagulation abnormalities were observed. Upon further inquiry, the patient reported a postoperative fever following his previous anesthesia. Based on the MH CGS, this case was scored 60 (rank 6 - “almost certain”). Genetic testing identified a novel heterozygous variant, c.7367 T > C, in exon 46 of the patient’s RYR1 gene, resulting in an amino acid substitution (sequences aligned to GenBank entry NM_000540.3). A summary of both cases is provided in Table 1. Table 1Demographic profile, phenotypic features and RYR1 mutations in two MH susceptible casesCase 1Case 2Age (yr)2331GenderFemaleMaleHistory of general anesthesia (with trigger agents)NoYesSurgeryCorrection of scoliosisRemoval of lumbar internal fixationMuscle stiffnessOvertNon-overtTrigger agentSevofluraneSevofluraneIntervals of trigger agent –clinical MH onset (min)250450Heart rate maximum (bpm)140150Core temperature maximum (℃)41.241.2The highest partial pressure of CO2 (mmHg)107103Plasma potassium maximum5.35.6Blood pressureHigh-dose noradrenaline hard to maintain within normal rageNo extra handling is requiredICU stay (days)83CK maximum (u·L− 1)35402484CTnI maximum (pg·mL− 1)672.1215.9Myoglobin maximum (ng·mL− 1)> 1200> 1200Cardiac function impairmentYesNoPulmonary edemaYesNoDICOvertNon-overtRenal failureYesNoCGS score50 +Rank 6, “Almost certain”50 +Rank 6, “Almost certain”RYR1 mutationExon334460Nucleotide changeprotein substitutionc.4718 C> T (previously published)p. (Pro1573Leu)c.7367 T > Cp. (Ile2456Thr)c.9100 A> Gp. (Lys3034Glu)Abbreviations: MH Malignant hyperthermia, min minute, bpm beat per minute, ICU Intensive care unit, CK Creatine kinase, CTnI Cardiac troponin I, DIC Disseminated intravascular coagulation, CRRT Disseminated intravascular coagulation, CGS score Clinical Grading Scale score Demographic profile, phenotypic features and RYR1 mutations in two MH susceptible cases 50 + Rank 6, “Almost certain” 50 + Rank 6, “Almost certain” Nucleotide change protein substitution c.4718 C> T (previously published) p. (Pro1573Leu) c.7367 T > C p. (Ile2456Thr) c.9100 A> G p. (Lys3034Glu) Abbreviations: MH Malignant hyperthermia, min minute, bpm beat per minute, ICU Intensive care unit, CK Creatine kinase, CTnI Cardiac troponin I, DIC Disseminated intravascular coagulation, CRRT Disseminated intravascular coagulation, CGS score Clinical Grading Scale score Discussion MH is an autosomal dominant pharmacogenetic disorder primarily triggered by halogenated volatile anesthetics, succinylcholine, or cisatracurium. Its diagnosis heavily relies on clinical manifestations, and delayed treatment can lead to catastrophic outcomes, including death. However, emerging evidence highlights an indolent form of MH, characterized by subtle and non-specific symptoms, which complicates clinical diagnosis [3]. Since the first reported case in 1960 involving halothane anesthesia, MH has been recognized as a refractory anesthetic emergency [4]. Exposure to triggering agents in susceptible individuals leads to sustained skeletal muscle hypermetabolism and contraction, a process that can progress to multi-organ failure unless halted by the specific antagonist dantrolene. It was long presumed that the severity of MH correlated with its rarity, with an estimated incidence of 1/15,000 to 1/75,000 across all racial groups [5]. However, recent studies suggest that the true prevalence of MH susceptibility may be significantly higher, with the MH Association estimating causative gene prevalence at 1:2000 to 1:3000 [6]. This discrepancy may be partly explained by MH’s broad clinical spectrum, which ranges from fulminant crises to mild, unrecognized symptoms. Multiple factors contribute to the variability in MH expression. The severity and timing of onset can differ based on the potency, dose, and duration of exposure to the triggering agent [7, 8]. This observation introduces the concept of the “incomplete penetrance” of an obligate genetic variant. MH manifestation is influenced by additional variables, including gender, with the incidence being twice as common in males [9]. Incomplete penetrance, as evidenced by nine gender-dependent RYR1 variants, underlies this phenomenon [10]. Studies indicate that the probability of developing MH among obligate RYR1 variant carriers exposed to triggers is approximately 0.25. This report details three missense variants, each causing a protein modification. The clinical presentations—one fulminant and one indolent—can be attributed to the distinct phenotypes associated with different RYR1 variants. The first case, a rare heterozygous carrier of two variants on distinct alleles leading to two amino acid changes, presented with a severe attack and complications. Similarly, another two RYR1 variants on distinct alleles described in two patients have stronger response in the muscle cell contraction test (IVCT) and clinical signs, have been documented [11]. Furthermore, individuals homozygous for RYR1 variants exhibit heightened sensitivity to triggers and increased muscle contracture forces [12], implying that inheriting two variant alleles may lead to a more pronounced phenotype due to greater disruption of protein architecture. Among the three variants reported, c.4718 C > T has been previously associated with congenital myopathy [13], while the pathogenicity of c.9100 A > G and c.7367T > C remains uncertain. According to the 2015 guidelines established by the American College of Medical Genetics and Genomics, genetic variants are categorized as benign, likely benign, likely pathogenic, or pathogenic [14]. Notably, about 80% of identified variants are unique to a single proband [15]. The RYR1 gene, with its 106 exons encoding a 5038-amino-acid residue protein, represents the largest known ion channel, harboring potential for numerous causative variants [16]. Disease-promoting variants are primarily concentrated in three evolutionarily conserved “hot spot” regions [16]. While the pathogenicity of the c.7367T > C variant (located in hot spot region 2) in our second case is uncertain, its location warrants further investigation into a potential causal relationship with MH. The c.9100 A > G variant in the first case lies outside a known hot spot [17], yet its pathogenicity cannot be dismissed without evaluation, given the increasing number of pathogenic variants identified outside these regions in recent years. Furthermore, high CGS scores can serve as a valuable diagnostic tool for clinical MH [18]. Therefore, further investigation is imperative to validate the causal association of MH with the RYR1 variants c.4718 C > T, c.9100 A > G, and c.7367T > C. Per European Malignant Hyperthermia Group (EMHG) guidelines, confirming a causal relationship for a novel RYR1 variant requires in vitro functional studies demonstrating a gain-of-function effect on intracellular calcium release. Currently, the EMHG accepts only 2 CACNA1S and 66 (pathogenic or likely pathogenic) RYR1 variants as diagnostic variants (http://www.emhg.org). This list, however, is not exhaustive and continues to expand with advancing genetic technologies that confirm the pathogenicity of more variants. Thus, functional characterization of the three variants discussed in this study is warranted and may contribute to expanding the repertoire of variants used in the molecular genetic diagnosis of MH susceptibility. Conclusion Based on the presented cases and discussion, it can be inferred that MH encompasses a spectrum of phenotypes characterized by subtle, non-specific, and ambiguous symptoms. This variability underscores that MH can present as either a severe, life-threatening crisis or a milder, self-limiting episode. The absence of adverse events during previous anesthetics cannot definitively exclude MH susceptibility. Additionally, the novel variants reported in this study may contribute to the international RYR1 variant database with further functional evidence and IVCT. Acknowledgements We would like to express our sincere gratitude to the two patients described in this article. We also extend our heartfelt thanks to the surgical team who performed the procedures and participated in the emergency management of the patients reported in this study. Abbreviations Beat per minute Calcium voltage-gated channel subunit alpha1 S Clinical Grading Scale Continuous renal replacement therapy Creatine kinase Cardiac troponin I Disseminated intravascular coagulation European Malignant Hyperthermia Group Intensive care unit Muscle cell contraction test Potassium ion Malignant hyperthermia Partial Pressure of Carbon Dioxide in Arterial Blood Ryanodine receptor 1 Authors’ contributions J.J.B. and Y.F. wrote the main manuscript text and W.M. contributed to the conception and substantively revised the manuscript. All authors reviewed the manuscript. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The authors confirm that the data supporting the findings of this study are available within the article. Declarations Ethics approval and consent to participate Not applicable. Consent for publication Written informed consent was obtained from the patients for the publication of their personal and clinical details, along with any identifying information, in this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The authors confirm that the data supporting the findings of this study are available within the article.